Biosimilar Development Center News Today

Sandoz has launched a new antibiotic production plant in Austria along with a biosimilar development center in Germany. The units are in line with the firm’s aim to strengthen sustainable development and supply of critical medicines in Europe and other regions of the world.

Sandoz will invest roughly $90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia, by 2026.

Basel: Sandoz has announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026.With this investment,...

Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026 New end-to-end drug substance and drug...